01:06 , Feb 17, 2017 |  BC Innovations  |  Strategy

Putting genes to the test

As new technologies fill the landscape of molecular diagnostics, two fault lines are becoming clear: next-generation sequencing versus PCR, and tumor biopsies versus ctDNA. But while stakeholders believe there’s room for it all, they warn...
07:00 , Apr 6, 2015 |  BC Week In Review  |  Company News

Agena Bioscience sales and marketing update

Agena launched the research use-only LungFUSION panel worldwide to identify anaplastic lymphoma kinase (ALK) , ret proto-oncogene (RET) and c-ros proto-oncogene 1 receptor tyrosine kinase (ROS1) gene fusions in non-small cell lung cancer (NSCLC). Agena...
07:00 , Jul 28, 2014 |  BC Week In Review  |  Company News

Agena Bioscience management update

Agena Bioscience Inc. , San Diego, Calif.   Business: Genomics, Diagnostic   Hired: Peter Dansky as CEO and a director, formerly the president of the molecular and cell biology division of Life Technologies Corp. ,...
07:00 , Jun 23, 2014 |  BC Week In Review  |  Clinical News

Impact Dx Factor V Leiden and Factor II Genotyping Test regulatory update

Sequenom said FDA granted 510(k) clearance to the Impact Dx Factor V Leiden and Factor II Genotyping Test for use as an aid in diagnosing patients with suspected thrombophilia and to its Impact Dx System...
07:00 , Jun 9, 2014 |  BC Week In Review  |  Company News

Agena Bioscience Inc., Sequenom deal

Sequenom sold its bioscience business to diagnostics company Agena for $31.8 million up front in cash. Sequenom is also eligible for up to $4 million in regulatory and sales milestones. The bioscience business, formerly known...